Center for Scientific Review; Notice of Closed Meetings, 19074 [2017-08293]
Download as PDF
<![CDATA[
19074
Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; AD Genetic
Variants in Human Cell Biology.
Date: May 23, 2017.
Time: 12:01 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Maurizio Grimaldi, MD,
Ph.D., Scientific Review Officer, National
Institute On Aging, National Institutes Of
Health, 7201 Wisconsin Avenue, Room
2C218, Bethesda, MD 20892, 301–496–9374,
grimaldim2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: April 20, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–08349 Filed 4–24–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Linking Provider Recommendation to
Adolescent HPV Uptake.
Date: May 16, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Tasmeen Weik, DRPH,
MPH, Scientific Review Officer, Center for
VerDate Sep<11>2014
17:42 Apr 24, 2017
Jkt 241001
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3141,
Bethesda, MD 20892, 301–827–6480, weikts@
mail.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group; Development—2
Study Section.
Date: May 25–26, 2017.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Nikko San Francisco, 222
Mason Street, San Francisco, CA 94102.
Contact Person: Rass M. Shayiq, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, (301) 435–
2359, shayiqr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 16–
323: Small Research Grants for Establishing
Basic Sciences Clinical Collaboration to
Understand Structural Birth Defects.
Date: May 26, 2017.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Nikko San Francisco, 222
Mason Street, San Francisco, CA 94102.
Contact Person: Rass M. Shayiq, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, (301) 435–
2359, shayiqr@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 19, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–08293 Filed 4–24–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Peter Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Live Attenuated Zika Virus Vaccine
Description of Technology
This application claims live
attenuated Zika viruses and vaccines,
attenuated chimeric Zika viruses and
vaccines, and multivalent immunogenic
compositions comprising Zika vaccines
and vaccines for other flaviviruses. The
chimeric Zika viruses claimed include a
first nucleotide sequence encoding at
least one structural protein from a Zika
virus (ZIKV), a second nucleotide
sequence encoding at least one
nonstructural protein from a first
flavivirus, and a third nucleotide
sequence of a 3’ untranslated region
from a second flavivirus. The
multivalent immunogenic compositions
claimed comprise an attenuated ZIKV
vaccine or an attenuated chimeric ZIKV
vaccine (or their combination) together
with one or more of a first attenuated
virus that is immunogenic against
dengue serotype 1, a second attenuated
virus that is immunogenic against
dengue serotype 2, a third attenuated
virus that is immunogenic against
dengue serotype 3, and a fourth
attenuated virus that is immunogenic
against dengue serotype 4. The present
disclosure also claims methods of
inducing immune responses, as well as
preventing ZIKV and another flavivirus,
e.g., dengue virus.
Such a chimeric vaccine candidate
may induce a humoral (antibody) and Tcell response to ZIKV, while the
nonstructural proteins of dengue virus
will likely induce a T-cell response. The
dengue platform also contains a deletion
in the TL2 stem-loop structure of the 3’
untranslated region (UTR), called D30
and D30/31 attenuating mutations. The
D30 deletion has proven to be one of the
defining characteristics of the successful
one dose dengue vaccine, which is
currently in a large scale (17,000
patient) clinical trial in Brazil.
This technology is available for
licensing for commercial development
E:\FR\FM\25APN1.SGM
25APN1
]]>Agencies
[Federal Register Volume 82, Number 78 (Tuesday, April 25, 2017)]
[Notices]
[Page 19074]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08293]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Linking Provider Recommendation to Adolescent HPV
Uptake.
Date: May 16, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Tasmeen Weik, DRPH, MPH, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3141, Bethesda, MD 20892, 301-
827-6480, weikts@mail.nih.gov.
Name of Committee: Cell Biology Integrated Review Group;
Development--2 Study Section.
Date: May 25-26, 2017.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hotel Nikko San Francisco, 222 Mason Street, San
Francisco, CA 94102.
Contact Person: Rass M. Shayiq, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182, MSC 7818, Bethesda, MD
20892, (301) 435-2359, shayiqr@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR 16-323: Small Research Grants for Establishing Basic
Sciences Clinical Collaboration to Understand Structural Birth
Defects.
Date: May 26, 2017.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hotel Nikko San Francisco, 222 Mason Street, San
Francisco, CA 94102.
Contact Person: Rass M. Shayiq, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182, MSC 7818, Bethesda, MD
20892, (301) 435-2359, shayiqr@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: April 19, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-08293 Filed 4-24-17; 8:45 am]
BILLING CODE 4140-01-P
